About

About us

Medical Travel Japan is a web site owned by Ceelabo, LLC, an internet advertising firm. The busines model of our site is a site directory advertisement that charges an annual fixed fee to the hospital or to the related companies, who want to register their hospitals in our directory of hospitals. 

What We Do

We provide information to both inbound (US, Europe, Middle East, Asia) and outbound (Japan) medical travellers.  

For the inbound medical travel, we had feedbacks from many patients to experience the complexity of hospital admission in Japan, and communication problems due to language barriers.

To overcome the difficulty, we decided to set up the helpdesk (support@japan-medical-tourism.com) responding to the patients seeking helps for hospital admissions or to find available treatments in Japanese hospitals. Helpdesk is managed on non-profit nature and answers to the questions related to the choices of treatment, hospital, insurance, and visa.  

In addition to giving the advise to the overseas patients, the task of our helpdesk is to remain faithful to the spirit of the humanitarian principle of hospitals for domestic and foreign patients. Among Japanese medical professionals, there have been criticisms for hospitals to be profit-oriented, but in the same veins, wide waves of supports by medics exist for the overseas patients to seek better treatments in Japan 

It is important that our service is not to favor rich patients or patients with solely financial merits, but intended to give patients an option for the treatments not available in their home countries, and an unbiased recommendation / referral to the best available hospitals, and access to the treatment with a fair cost.

Neutrality

We aim to be neutral to all sides, i.e., patient, medical traveller, coordinator / facilitator, hospital, travel agency or government. Although our site is funded by the participating hospitals in our hospital directory, we do not have any partnering relations with hospitals other than charging index registration fees. Registration is simply the means to register a set of information such as special treatments, division, and references in our hospital directory. For this reason, the neutrality is ensured to prevail in our relationship with hospitals.  

Our hospital ranking (under construction) is fully based on academic / professional journals, or governmental sources. Our mission is to check the validity of statistics, and data, and ensure the accuracy of the ranking after the incorporation of different, often incontiguous data. Should there be evidences for the overseas hospitals having the good clinical outcomes, we recommend the Japanese patients to go overseas to take the treatment outside Japan, or vice versa.

Site Policy

Our site is not affiliated with any organizations, agencies, business entity other than our advertizement business. We remain entirely free of financial benefits for referral or advise to patients.

All personal information provided by patients is kept in strict confidence, and to be discarded once the support request is closed.

However, in cases that patients agreed to disclose the personal information to the medical institutions, the submitted materials are managed under the privacy policy of each institution. 

International Hospital Ranking

Cancer Adoptive Cell Immunotherapy in Japan

Cell based Immunotherapy (Autologous immune enhancement therapy) has been more frequently practised in Japan.Techniques to harvest the cells are extremely intricate and delicate processes. For the treatments to be rountinely available to the cancer patients apart from the clinical trials, advanced engineering cell reprocessing center must be available with good corroboration with the hospitals.

Since Japan made the Immuno-Cell Therapy to be a part of health care systems, the cell processing centers (CPCs) rapidly increased in the past decades. For the therapy of high complexity such as dendritic cell / autologous enhancement immunotherapy to be regularly practiced in the hospital, those CPCs were essential, and this explains why much of innovations in cell based cancer immunotherapy took place in Japan. 

Endoscopic Submucosal Dissection (ESD) \ Endoscopic Mucosal Resection (EMR) in Japan

Both EMR and ESD was originally developed in Japan. EMR / ESD (endoscopic biopsy or polyp resection procedure on gastrointestinal tract) is the area that Japanese surgeons are leading the research at forefront. It is the minimally invasive endoscopic procedure that conserves organs / tissues, and patients can be discharged from the hospital in the same day or a week after the operations. It is usually applicable to early stage cancer / tumor, and improves the post-surgical health conditions such as loss of appetite, fever, chills, pains and life-long medication.

Proton Beam Therapy

Currently there are about 31 proton (or carbon ion) therapy facilities in the world, 8 of which is built in Japan. Proton Beam Therapy is much less invasive than other radiotherapy treatments, and can treat the cancer without incision of the body, and with much less side effects than X-ray treatments. Japan has invested in Proton beam therapy (PBT) / Carbon Ion Therapy infrastructure for a long time, and clinical level studies are numerous and thus well experienced with all kinds of localized tumors.

Radiofrequency Ablation (RFA) on Liver cancer (Hepatocellular carcinoma)

Japan has been leading the RFA intervention technology for a long time, and the yearly number of RFA interventions in Japan currently exceeds that of United States and China. (See the Table below.) Survival rates for the patients undergoing the RFA are not different from those of surgery. But the surgery is harder to be operated multiple times, whereas the RFA is not restricted by the number of interventions or by the presence of Hepatitis.  For this reason, RFA becomes a standard treatment in Japan.

Yearly volume of RFA on Liver Cancer
Japan 34,000
US 14,000
China 9,500

Table: Yearly number of Radiofrequency ablation of Liver or hepatic tumors by country.

Regenerative Medicine on Dilated Cardiomyopathy, or Myocardial Infarction

Recent technological advances in cell sheets engineering extended to the pre-clinical trial of the treatment of heart disease patients often in need for the heart transplant.

Micro-Catheter treatments on varicose veins (including the veins below the knee)

In japan, complex operations towards varicose veins below the knee are established with safey and high response rates. Various catheter and micro-catheter devices are extensively used, and some of them are only available in Japan.

Cancer and Heart Disease Treatment in Japan  

Medical technology in Japan for cancer screening and gastrointestinal diseases are known to be very strong, supported by good clinical statistics, i.e., high five year survival rate after the surgery (or radiology / chemotherapy) among the colon, rectal, stomach, and esophageal cancer patients as well as liver, lung, and larynx cancer (See Table below). 

Since Japanese health agency is notoriously slow and counter-productive when it comes to the approval of new drugs, Japan's hospitals and patients suffered for so long by the technology lag from the rest of the world. Ironically, these regulatory problems lead physicians to the innovations in the fields other than drug discoveries, i.e., in the surgical / laparoscopic, endoscopic, micro-catheter procedures, cell based immunotherapy / vaccinations, radiation (carbon ion and proton beam), and regenerative medicine (iPS cells, cell sheets).

Since the Japanese physicians had less options in chemotherapy, they had more opportunities in experiencing difficult surgeries, and tried the new treatments due to the low availability of new drugs. Thus, many exotic and unique medical technologies emerged out of the isolations casued by the incompetence of Japanese health agency.

Site (Survival Rate:  %)

7 Cancer Registrates in Japan

US SEER Program Eurocare-3
Esophagus 25 14 10
Stomach 58 22 23
Colon 66 62 51
Rectum 63 63 48
Liver 17 7 7
Gallbladder 18 16 12
Pancreas 6 4 4
Larynx 77 65 62
Lung, bronchus 20 15 11